JP2006503868A - 鼻に投与可能な製薬学的調剤およびその製造 - Google Patents
鼻に投与可能な製薬学的調剤およびその製造 Download PDFInfo
- Publication number
- JP2006503868A JP2006503868A JP2004542079A JP2004542079A JP2006503868A JP 2006503868 A JP2006503868 A JP 2006503868A JP 2004542079 A JP2004542079 A JP 2004542079A JP 2004542079 A JP2004542079 A JP 2004542079A JP 2006503868 A JP2006503868 A JP 2006503868A
- Authority
- JP
- Japan
- Prior art keywords
- buffer
- agent
- pharmaceutical
- malic acid
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 239000000872 buffer Substances 0.000 claims abstract description 49
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000001630 malic acid Substances 0.000 claims abstract description 40
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 39
- 235000011090 malic acid Nutrition 0.000 claims abstract description 39
- 239000003755 preservative agent Substances 0.000 claims abstract description 33
- 239000000243 solution Substances 0.000 claims abstract description 33
- 230000002335 preservative effect Effects 0.000 claims abstract description 30
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 25
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 239000002357 osmotic agent Substances 0.000 claims abstract description 13
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract description 13
- 241000219289 Silene Species 0.000 claims abstract description 11
- 239000013543 active substance Substances 0.000 claims abstract description 11
- 229910052918 calcium silicate Inorganic materials 0.000 claims abstract description 11
- 239000000839 emulsion Substances 0.000 claims abstract description 11
- 239000000080 wetting agent Substances 0.000 claims abstract description 10
- 238000009472 formulation Methods 0.000 claims abstract description 9
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims abstract description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract description 4
- 239000010452 phosphate Substances 0.000 claims abstract description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 239000007853 buffer solution Substances 0.000 claims description 11
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims description 8
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims description 8
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims description 8
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 claims description 7
- 229960004281 desmopressin Drugs 0.000 claims description 6
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000000172 allergic effect Effects 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- PZJFUNZDCRKXPZ-UHFFFAOYSA-N 2,5-dihydro-1h-tetrazole Chemical compound C1NNN=N1 PZJFUNZDCRKXPZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000150 Sympathomimetic Substances 0.000 claims description 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 4
- 229960000265 cromoglicic acid Drugs 0.000 claims description 4
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 229960005016 naphazoline Drugs 0.000 claims description 4
- 229960001528 oxymetazoline Drugs 0.000 claims description 4
- 229960001802 phenylephrine Drugs 0.000 claims description 4
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 230000001975 sympathomimetic effect Effects 0.000 claims description 4
- 229960000833 xylometazoline Drugs 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 235000021317 phosphate Nutrition 0.000 claims 4
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims 3
- 108010037003 Buserelin Proteins 0.000 claims 3
- 102000055006 Calcitonin Human genes 0.000 claims 3
- 108060001064 Calcitonin Proteins 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 3
- 108010021717 Nafarelin Proteins 0.000 claims 3
- 102400000050 Oxytocin Human genes 0.000 claims 3
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims 3
- 101800000989 Oxytocin Proteins 0.000 claims 3
- 239000003470 adrenal cortex hormone Substances 0.000 claims 3
- 229960004574 azelastine Drugs 0.000 claims 3
- 229940092705 beclomethasone Drugs 0.000 claims 3
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 3
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims 3
- 229960002719 buserelin Drugs 0.000 claims 3
- 229960004015 calcitonin Drugs 0.000 claims 3
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 claims 3
- -1 gonadorenin Chemical compound 0.000 claims 3
- 229940088597 hormone Drugs 0.000 claims 3
- 239000005556 hormone Substances 0.000 claims 3
- 229960004861 indanazoline Drugs 0.000 claims 3
- KUCWWEPJRBANHL-UHFFFAOYSA-N indanazoline Chemical compound C=12CCCC2=CC=CC=1NC1=NCCN1 KUCWWEPJRBANHL-UHFFFAOYSA-N 0.000 claims 3
- 229960001120 levocabastine Drugs 0.000 claims 3
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 claims 3
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 claims 3
- 229960002333 nafarelin Drugs 0.000 claims 3
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims 3
- 229960001723 oxytocin Drugs 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- 229960001262 tramazoline Drugs 0.000 claims 3
- QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 claims 3
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 3
- 229960005294 triamcinolone Drugs 0.000 claims 3
- 150000001242 acetic acid derivatives Chemical class 0.000 claims 2
- 150000001860 citric acid derivatives Chemical class 0.000 claims 2
- 229940124579 cold medicine Drugs 0.000 claims 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000007922 nasal spray Substances 0.000 description 16
- 229940097496 nasal spray Drugs 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 210000001331 nose Anatomy 0.000 description 7
- 235000011121 sodium hydroxide Nutrition 0.000 description 7
- 230000001886 ciliary effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 210000004240 ciliary body Anatomy 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940126601 medicinal product Drugs 0.000 description 3
- 210000002850 nasal mucosa Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- YGWFCQYETHJKNX-UHFFFAOYSA-N 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1h-imidazol-3-ium;chloride Chemical compound [Cl-].CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCC[NH2+]1 YGWFCQYETHJKNX-UHFFFAOYSA-N 0.000 description 2
- 229940032555 benzalkonium chloride 0.1 mg/ml Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 2
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229960001095 xylometazoline hydrochloride Drugs 0.000 description 2
- IHOWSFVYYZTGSY-FOIRCHMTSA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N.OC(=O)[C@@H](N)CCCN=C(N)N.OC(=O)[C@@H](N)CCCN=C(N)N.OC(=O)CC(O)(C(O)=O)CC(O)=O IHOWSFVYYZTGSY-FOIRCHMTSA-N 0.000 description 1
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000033999 Device damage Diseases 0.000 description 1
- 206010022528 Interactions Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229960002845 desmopressin acetate Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- CCTIOCVIZPCTGO-BYPYZUCNSA-N phosphoarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)NP(O)(O)=O CCTIOCVIZPCTGO-BYPYZUCNSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0154002A AT413078B (de) | 2002-10-10 | 2002-10-10 | Verwendung eines puffers auf basis von apfelsäure für die herstellung einer nasal applizierbaren zubereitung |
| PCT/AT2003/000306 WO2004032896A1 (de) | 2002-10-10 | 2003-10-09 | Nasal applizierbare pharmazeutische zubereitung und deren herstellung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006503868A true JP2006503868A (ja) | 2006-02-02 |
| JP2006503868A5 JP2006503868A5 (enExample) | 2006-09-21 |
Family
ID=32074994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004542079A Withdrawn JP2006503868A (ja) | 2002-10-10 | 2003-10-09 | 鼻に投与可能な製薬学的調剤およびその製造 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060127317A1 (enExample) |
| EP (1) | EP1549288A1 (enExample) |
| JP (1) | JP2006503868A (enExample) |
| AT (1) | AT413078B (enExample) |
| AU (1) | AU2003266811A1 (enExample) |
| CA (1) | CA2501760A1 (enExample) |
| NO (1) | NO20052251L (enExample) |
| PL (1) | PL375762A1 (enExample) |
| WO (1) | WO2004032896A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010517956A (ja) * | 2007-02-02 | 2010-05-27 | クレウェル メウセルバッハ ゲー・エム・ベー・ハー | シスタス抽出物（ＣｉｓｔｕｓＥｘｔｒａｃｔｓ） |
| JP2016532660A (ja) * | 2013-10-08 | 2016-10-20 | イノファーマ インク | アプレピタント経口液体製剤 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130213393A1 (en) | 2009-12-22 | 2013-08-22 | Evoke Pharma, Inc. | Nasal formulations of metoclopramide |
| US11517545B2 (en) | 2016-12-15 | 2022-12-06 | Evoke Pharma, Inc. | Treatment of moderate and severe gastroparesis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5514670A (en) * | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| AT409081B (de) * | 2000-02-16 | 2002-05-27 | Gebro Pharma Gmbh | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung |
-
2002
- 2002-10-10 AT AT0154002A patent/AT413078B/de active
-
2003
- 2003-10-09 US US10/530,969 patent/US20060127317A1/en not_active Abandoned
- 2003-10-09 EP EP03747695A patent/EP1549288A1/de not_active Withdrawn
- 2003-10-09 WO PCT/AT2003/000306 patent/WO2004032896A1/de not_active Ceased
- 2003-10-09 PL PL03375762A patent/PL375762A1/xx not_active Application Discontinuation
- 2003-10-09 AU AU2003266811A patent/AU2003266811A1/en not_active Abandoned
- 2003-10-09 JP JP2004542079A patent/JP2006503868A/ja not_active Withdrawn
- 2003-10-09 CA CA002501760A patent/CA2501760A1/en not_active Abandoned
-
2005
- 2005-05-09 NO NO20052251A patent/NO20052251L/no not_active Application Discontinuation
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010517956A (ja) * | 2007-02-02 | 2010-05-27 | クレウェル メウセルバッハ ゲー・エム・ベー・ハー | シスタス抽出物（ＣｉｓｔｕｓＥｘｔｒａｃｔｓ） |
| JP2016532660A (ja) * | 2013-10-08 | 2016-10-20 | イノファーマ インク | アプレピタント経口液体製剤 |
| JP2019196367A (ja) * | 2013-10-08 | 2019-11-14 | イノファーマ インク | アプレピタント経口液体製剤 |
| JP2021169504A (ja) * | 2013-10-08 | 2021-10-28 | イノファーマ インク | アプレピタント経口液体製剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004032896A1 (de) | 2004-04-22 |
| NO20052251L (no) | 2005-05-09 |
| PL375762A1 (en) | 2005-12-12 |
| US20060127317A1 (en) | 2006-06-15 |
| AT413078B (de) | 2005-11-15 |
| ATA15402002A (de) | 2005-04-15 |
| AU2003266811A1 (en) | 2004-05-04 |
| EP1549288A1 (de) | 2005-07-06 |
| CA2501760A1 (en) | 2004-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100889170B1 (ko) | 안구 건조의 치료에 있어서 리멕솔론의 용도 | |
| JP7756953B2 (ja) | マグネシウム含有オキシトシン製剤および使用の方法 | |
| US10792288B2 (en) | Preservative free brimonidine and timolol solutions | |
| JP2003512325A (ja) | 感冒およびインフルエンザ様症状の予防並びに治療用組成物、並びにそれらの使用方法 | |
| JP2015110672A (ja) | ビマトプロストおよびブリモニジンの固定用量の組み合わせ | |
| JP2002003364A (ja) | 点眼剤、眼科用組成物及び吸着抑制方法 | |
| CN103068364A (zh) | 不含防腐剂的比马前列素和噻吗洛尔溶液 | |
| EP1283043B1 (en) | Ophthalmic solution | |
| JPH02196716A (ja) | 薬学的溶液 | |
| JP4752987B2 (ja) | 外用剤組成物 | |
| JP2006503868A (ja) | 鼻に投与可能な製薬学的調剤およびその製造 | |
| JP2008517937A (ja) | 眼科用組成物及びその使用方法 | |
| JP4801300B2 (ja) | 外用液状組成物 | |
| JP2003073303A (ja) | 眼局所用液剤の清涼化作用の持続方法 | |
| JP7114668B2 (ja) | エピナスチン又はその塩を含有する花粉破裂抑制剤 | |
| JP2003055201A (ja) | ビタミンａ類含有可溶化組成物及びビタミンａ類の安定化方法 | |
| JPS63502270A (ja) | 散瞳作用を有する眼科用医薬組成物 | |
| ZA200502883B (en) | Nasally applicable pharmaceutical preparation and the production thereof | |
| HK40108141A (en) | Magnesium-containing oxytocin formulations and methods of use | |
| JP2004503486A (ja) | 新規な水性抗炎症医薬製剤 | |
| HK40004045A (en) | Preservative free brimonidine and timolol solutions | |
| JP2011105764A (ja) | 外用剤組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060803 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060803 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20080509 |